128,700 Shares in Alto Neuroscience, Inc. (NYSE:ANRO) Purchased by Stifel Financial Corp

Stifel Financial Corp bought a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 128,700 shares of the company’s stock, valued at approximately $544,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANRO. Marshall Wace LLP acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at $3,542,000. Franklin Resources Inc. increased its stake in Alto Neuroscience by 95.3% during the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after purchasing an additional 595,673 shares in the last quarter. Barclays PLC lifted its position in Alto Neuroscience by 872.7% in the 3rd quarter. Barclays PLC now owns 29,599 shares of the company’s stock valued at $339,000 after acquiring an additional 26,556 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Alto Neuroscience by 543.4% in the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company’s stock worth $278,000 after purchasing an additional 20,536 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alto Neuroscience in the 4th quarter valued at about $74,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ANRO shares. HC Wainwright began coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.40.

Alto Neuroscience Trading Up 0.9%

Shares of ANRO stock opened at $2.21 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The company has a market cap of $59.83 million, a PE ratio of -0.87 and a beta of 1.87. Alto Neuroscience, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $17.55. The stock’s fifty day moving average price is $2.49 and its two-hundred day moving average price is $3.49.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. Equities analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.